Treatment of androgenic disorders with dexamethasone: dose-response relationship for suppression of dehydroepiandrosterone sulfate.
Abstract
Glucocorticoids are effective in suppressing androgens in many women whose levels of these steroids are elevated. Their use has been controversial because of inconsistent reports about efficacy and concern about safety. We investigated the dose-response relationship for suppression of dehydroepiandrosterone sulfate (DHEAS) with the use of dexamethasone. Thirty women with an initial DHEAS value of greater than or equal to 300 micrograms/dl were studied. All had cystic or inflammatory acne, hirsutism, or androgenic alopecia. Dexamethasone was given as a single bedtime dosage of 0.125, 0.250, or 0.375 mg. Mean dosage required for suppression was 0.256 mg daily. Suppression of the DHEAS level to less than or equal to 200 micrograms/dl was achieved with 0.125 mg in 25% of women, 0.250 mg in an additional 50%, and 0.375 mg in a further 20%. Most patients were taking spironolactone when the study was performed. Effective suppression is attained with dexamethasone doses significantly lower than previously thought. Use of these doses was not associated with a significant incidence of adverse effects.
Used In Evidence Reviews
Similar Papers
Journal of the American Academy of Dermatology · 2005
Evaluation and treatment of male and female pattern hair loss.
The British journal of dermatology · 2005
Treatment of female pattern hair loss with oral antiandrogens.
International journal of dermatology · 2018
Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone.
International journal of women's dermatology · 2018
Female pattern hair loss: A clinical, pathophysiologic, and therapeutic review.
Dermatologic clinics · 1998
Hair regrowth. Therapeutic agents.
International journal of nanomedicine · 2014